Filter

Refine by collections

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 10 of 239 items for :

  • treatment initiation x
Clear All
Xi Wang Department of Obstetrics and Gynaecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

Search for other papers by Xi Wang in
Google Scholar
PubMed Close
and
Qi Yu Department of Obstetrics and Gynaecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

Search for other papers by Qi Yu in
Google Scholar
PubMed Close

. Letrozole initiation and treatment duration The mean age at letrozole initiation was 4.5 ± 2.6 years. The letrozole dose differed between subjects. Six patients from the initial letrozole pilot study were dosed according to the parameters of that study (a

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-18-0344
Volume/Issue:
Volume 7: Issue 12
Open access
Agnieszka Pazderska Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK
Department of Endocrinology, St James’s Hospital, Dublin, Ireland

Search for other papers by Agnieszka Pazderska in
Google Scholar
PubMed Close
,
Yaasir Mamoojee Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK

Search for other papers by Yaasir Mamoojee in
Google Scholar
PubMed Close
,
Satish Artham Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK

Search for other papers by Satish Artham in
Google Scholar
PubMed Close
,
Margaret Miller Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK

Search for other papers by Margaret Miller in
Google Scholar
PubMed Close
,
Stephen G Ball Department of Endocrinology, Central Manchester University Hospitals, Manchester, UK
Department of Endocrinology, University of Manchester, Manchester, UK

Search for other papers by Stephen G Ball in
Google Scholar
PubMed Close
,
Tim Cheetham Endocrine Research Group, Institute of Genetic Medicine, University of Newcastle-upon-Tyne, Newcastle upon Tyne, UK
Department of Paediatric Endocrinology & Diabetes, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK

Search for other papers by Tim Cheetham in
Google Scholar
PubMed Close
, and
Richard Quinton Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK
Endocrine Research Group, Institute of Genetic Medicine, University of Newcastle-upon-Tyne, Newcastle upon Tyne, UK

Search for other papers by Richard Quinton in
Google Scholar
PubMed Close

international online patient survey), whose data collection was separated by over 20 years, found the median age of initiation of any meaningful treatment to be 18–19 years ( 4 , 5 ). The predominant reasons for treatment delay emerging from these studies are

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-17-0241
Volume/Issue:
Volume 7: Issue 1
Open access
Peter Wolf Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, Le Kremlin-Bicêtre, France
Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

Search for other papers by Peter Wolf in
Google Scholar
PubMed Close
,
Alexandre Dormoy Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, Le Kremlin-Bicêtre, France

Search for other papers by Alexandre Dormoy in
Google Scholar
PubMed Close
,
Luigi Maione Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, Le Kremlin-Bicêtre, France

Search for other papers by Luigi Maione in
Google Scholar
PubMed Close
,
Sylvie Salenave Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, Le Kremlin-Bicêtre, France

Search for other papers by Sylvie Salenave in
Google Scholar
PubMed Close
,
Jacques Young Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, Le Kremlin-Bicêtre, France

Search for other papers by Jacques Young in
Google Scholar
PubMed Close
,
Peter Kamenický Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, Le Kremlin-Bicêtre, France

Search for other papers by Peter Kamenický in
Google Scholar
PubMed Close
, and
Philippe Chanson Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, Le Kremlin-Bicêtre, France

Search for other papers by Philippe Chanson in
Google Scholar
PubMed Close

hormonal substitution was not modified during treatment with pasireotide. The therapeutic indication for the initiation of pasireotide was resistance to first-generation SRLs in 25 out of 33 patients (76%) or side effects of pegvisomant in 4 out of 33

Article Type:
Research Article
Collections:
Metabolic Syndrome and Diabetes
DOI:
https://doi.org/10.1530/EC-22-0296
Volume/Issue:
Volume 11: Issue 12
Open access
Mark R Postma Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Search for other papers by Mark R Postma in
Google Scholar
PubMed Close
,
Pia Burman Department of Endocrinology, Skane University Hospital Malmö, University of Lund, Lund, Sweden

Search for other papers by Pia Burman in
Google Scholar
PubMed Close
, and
André P van Beek Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Search for other papers by André P van Beek in
Google Scholar
PubMed Close

increasingly difficult ( 6 , 7 , 8 ). It is not known whether these changes in SD scores and the likely association of delayed initiation of GHRT result in poorer outcomes. In paediatric growth hormone therapy, it is well known that age of treatment onset

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-20-0098
Volume/Issue:
Volume 9: Issue 7
Open access
Alicia Romano Department of Pediatrics, New York Medical College, Valhalla, New York, USA

Search for other papers by Alicia Romano in
Google Scholar
PubMed Close
,
Juan Pablo Kaski Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital & UCL Institute of Cardiovascular Science, London, UK

Search for other papers by Juan Pablo Kaski in
Google Scholar
PubMed Close
,
Jovanna Dahlgren Department of Paediatrics, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden

Search for other papers by Jovanna Dahlgren in
Google Scholar
PubMed Close
,
Nicky Kelepouris US Medical Affairs, Novo Nordisk Inc., Plainsboro, New Jersey, USA

Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed Close
,
Alberto Pietropoli Global Medical Affairs, Novo Nordisk Health Care AG, Zurich, Switzerland

Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed Close
,
Tilman R Rohrer Department of Pediatric Endocrinology, University Children’s Hospital, Saarland University Medical Center, Homburg, Germany

Search for other papers by Tilman R Rohrer in
Google Scholar
PubMed Close
, and
Michel Polak Paediatric Endocrinology, Diabetology and Gynaecology Department, Hôpital Universitaire Necker Enfants-Malades, AP-HP, Université de Paris, Imagine Institute, Paris, France

Search for other papers by Michel Polak in
Google Scholar
PubMed Close

events In total, 22 (5.3%) patients with NS experienced 34 safety events (Supplementary Table 2). Adverse reactions (NSARs or SARs) occurred in 18 (4.4%) patients after the initiation of GH treatment. Of the 24 NSARs, the most common were headache

Article Type:
Research Article
Collections:
Cardiovascular
DOI:
https://doi.org/10.1530/EC-21-0549
Volume/Issue:
Volume 11: Issue 1
Open access
Yuka Goto Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume-city, Fukuoka, Japan

Search for other papers by Yuka Goto in
Google Scholar
PubMed Close
,
Yoshie Otsuka Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume-city, Fukuoka, Japan

Search for other papers by Yoshie Otsuka in
Google Scholar
PubMed Close
,
Kenji Ashida Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume-city, Fukuoka, Japan

Search for other papers by Kenji Ashida in
Google Scholar
PubMed Close
,
Ayako Nagayama Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume-city, Fukuoka, Japan

Search for other papers by Ayako Nagayama in
Google Scholar
PubMed Close
,
Nao Hasuzawa Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume-city, Fukuoka, Japan

Search for other papers by Nao Hasuzawa in
Google Scholar
PubMed Close
,
Shimpei Iwata Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume-city, Fukuoka, Japan

Search for other papers by Shimpei Iwata in
Google Scholar
PubMed Close
,
Kento Hara Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume-city, Fukuoka, Japan

Search for other papers by Kento Hara in
Google Scholar
PubMed Close
,
Munehisa Tsuruta Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume-city, Fukuoka, Japan

Search for other papers by Munehisa Tsuruta in
Google Scholar
PubMed Close
,
Nobuhiko Wada Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume-city, Fukuoka, Japan

Search for other papers by Nobuhiko Wada in
Google Scholar
PubMed Close
,
Seiichi Motomura Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume-city, Fukuoka, Japan
Division of Endocrinology and Metabolism, Diabetes Center, Kurume Medical Center, Kokubu-machi, Kurume-city, Fukuoka, Japan

Search for other papers by Seiichi Motomura in
Google Scholar
PubMed Close
,
Yuji Tajiri Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume-city, Fukuoka, Japan
Division of Endocrinology and Metabolism, Diabetes Center, Kurume Medical Center, Kokubu-machi, Kurume-city, Fukuoka, Japan

Search for other papers by Yuji Tajiri in
Google Scholar
PubMed Close
, and
Masatoshi Nomura Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume-city, Fukuoka, Japan

Search for other papers by Masatoshi Nomura in
Google Scholar
PubMed Close

glucose consumption rate ( 12 ) in the muscle. However, it remained unclear whether SGLT2 inhibitor administration can improve insulin sensitivity and rapidly reduce plasma glucose concentrations in humans during the early phase of treatment initiation

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-20-0082
Volume/Issue:
Volume 9: Issue 7
Open access
Anastasia P Athanasoulia-Kaspar Max Planck Institute of Psychiatry, Department of Internal Medicine, Endocrinology and Clinical Chemistry, Munich, Germany

Search for other papers by Anastasia P Athanasoulia-Kaspar in
Google Scholar
PubMed Close
,
Kathrin H Popp Max Planck Institute of Psychiatry, Department of Internal Medicine, Endocrinology and Clinical Chemistry, Munich, Germany

Search for other papers by Kathrin H Popp in
Google Scholar
PubMed Close
, and
Gunter Karl Stalla Max Planck Institute of Psychiatry, Department of Internal Medicine, Endocrinology and Clinical Chemistry, Munich, Germany

Search for other papers by Gunter Karl Stalla in
Google Scholar
PubMed Close

psychiatric history and developed the symptoms after initiation of the dopamine agonist treatment. The dose of DAs was variable and symptoms were present regardless of the type of DAs as cabergoline, bromocriptine and quinagolide were implicated as treatment

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-18-0030
Volume/Issue:
Volume 7: Issue 2
Open access
Jaafar Jaafar Division of Endocrinology and Diabetology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

Search for other papers by Jaafar Jaafar in
Google Scholar
PubMed Close
,
Eugenio Fernandez Department of Oncology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

Search for other papers by Eugenio Fernandez in
Google Scholar
PubMed Close
,
Heba Alwan Division of Endocrinology and Diabetology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

Search for other papers by Heba Alwan in
Google Scholar
PubMed Close
, and
Jacques Philippe Division of Endocrinology and Diabetology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

Search for other papers by Jacques Philippe in
Google Scholar
PubMed Close

onset of hypothyroidism and hyperT in patients treated with durvalumab was 42 and 43 days, respectively. In fact, the range of time to the occurrence of a thyroid-related iAE was very large and varied from 1 day after treatment initiation to 31 months

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-18-0079
Volume/Issue:
Volume 7: Issue 5
Open access
Hélène Lasolle Fédération d’Endocrinologie, Centre de Référence Maladies Rares Hypophysaires HYPO, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France

Search for other papers by Hélène Lasolle in
Google Scholar
PubMed Close
,
Amandine Ferriere Service d’endocrinologie, diabète et nutrition, Hôpital Haut Lévêque, CHU de Bordeaux, Bordeaux, France
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France

Search for other papers by Amandine Ferriere in
Google Scholar
PubMed Close
,
Alexandre Vasiljevic Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Centre de Pathologie et de Neuropathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France

Search for other papers by Alexandre Vasiljevic in
Google Scholar
PubMed Close
,
Sandrine Eimer UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Service d’anatomo-pathologie, Hopital Pellegrin, CHU de Bordeaux, Bordeaux, France

Search for other papers by Sandrine Eimer in
Google Scholar
PubMed Close
,
Marie-Laure Nunes Service d’endocrinologie, diabète et nutrition, Hôpital Haut Lévêque, CHU de Bordeaux, Bordeaux, France

Search for other papers by Marie-Laure Nunes in
Google Scholar
PubMed Close
, and
Antoine Tabarin Service d’endocrinologie, diabète et nutrition, Hôpital Haut Lévêque, CHU de Bordeaux, Bordeaux, France
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France

Search for other papers by Antoine Tabarin in
Google Scholar
PubMed Close

/dL) requiring initiation of insulin treatment and lack of control of IGF-1 ( n , 2: Table 1 ) in one patient treated with 60 mg/month. Eleven patients initially treated with 40 mg/month ( n  = 7) and 60 mg/month ( n  = 4) continued to be treated with

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-19-0332
Volume/Issue:
Volume 8: Issue 10
Open access
Selma Flora Nordqvist Department of Medical Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Search for other papers by Selma Flora Nordqvist in
Google Scholar
PubMed Close
,
Victor Brun Boesen Department of Medical Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Search for other papers by Victor Brun Boesen in
Google Scholar
PubMed Close
,
Åse Krogh Rasmussen Department of Medical Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed Close
,
Ulla Feldt-Rasmussen Department of Medical Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed Close
,
Laszlo Hegedüs Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed Close
,
Steen Joop Bonnema Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

Search for other papers by Steen Joop Bonnema in
Google Scholar
PubMed Close
,
Per Karkov Cramon Department of Clinical Physiology and Nuclear Medicine, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

Search for other papers by Per Karkov Cramon in
Google Scholar
PubMed Close
,
Torquil Watt Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Department of Internal Medicine, Herlev Gentofte Hospital, Copenhagen, Denmark

Search for other papers by Torquil Watt in
Google Scholar
PubMed Close
,
Mogens Groenvold Department of Public Health, University of Copenhagen, Copenhagen, Denmark
Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark

Search for other papers by Mogens Groenvold in
Google Scholar
PubMed Close
, and
Jakob Bue Bjorner Department of Public Health, University of Copenhagen, Copenhagen, Denmark
National Research Centre for the Working Environment, Copenhagen, Denmark
QualityMetric Incorporated, LLC, Johnston, Rhode Island, USA

Search for other papers by Jakob Bue Bjorner in
Google Scholar
PubMed Close

University Hospital), were invited to complete ThyPRO prior to and 6 weeks after treatment initiation. At follow-up, patients also rated their change since baseline; both overall and for each of 13 specific domains measured by ThyPRO. Aiming at samples around

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-21-0026
Volume/Issue:
Volume 10: Issue 3
Open access